Table 2.
The major results of the two randomized controlled trials.
| Groups | EuLITE (39) | MYRE (40) | ||
|---|---|---|---|---|
| HCO-HD | HF-HD | HCO-HD | HF-HD | |
| Patients | 43 | 47 | 46 a | 48 |
| Study period | 2008–2013 | 2011–2016 | ||
| Area | UK and Germany | France | ||
| Age (years) | 66 | 65 | 68 | 69 |
| Serum creatinine (μmol/L) | 623 | 499 | 566 | 645 |
| Previous kidney disease (%) | 7 | 2 | 6 b | 17 b |
| Serum FLCs concentration (mg/L) | κ 9,300 λ 7,200 |
κ 11,600 λ 7,200 |
6590 | 5230 |
| Bone marrow plasma cells (%) | NA | NA | 38 | 31 |
| Albumin (g/L) | 37 | 38 | 32 | 34 |
| First-line chemotherapy | BAD | BD | ||
| Follow-up (months) | 24 | 17.5 c | ||
| Hemodialysis independence rate at 3 months (%) | 56 | 51 | 41 | 33 |
| Myeloma response rate at 3 months (%) | NA | NA | 89 | 63 |
| Hemodialysis independence rate at 6 months (%) | 58 | 66 | 57 | 35 |
| Myeloma response rate at 6 months (%) | 63 | 72 | 78 | 60 |
| Hemodialysis independence rate at 12 months (%) | 58 | 66 | 61 | 38 |
| Myeloma response rate at 12 months (%) | 42 | 68 | NA | NA |
| Death rate at 12 months (%) | NA | NA | 20 | 21 |
| Death rate at end point (%) | 37 | 19 | 28 | 33 |
NA, not available or could not obtain all of the participants’ detailed information; HCO-HD, high-cutoff hemodialysis; HF-HD, high-flux hemodialysis; FLCs, free light chains; BD, bortezomib and dexamethasone; BAD, bortezomib, doxorubicin, and dexamethasone.
Age, serum creatinine, serum FLC concentration, bone marrow plasma cells, and albumin are presented as the mean or median.
Hemodialysis independence is defined as sustained renal recovery without extracorporeal techniques after treatment.
Data show that 46 patients were included in the primary analysis.
Data represent patients with previous kidney diseases with an estimated glomerular filtration rate greater than 30 ml/min/1.73 m2.
Data represent a median follow-up of 17.5 months (interquartile range, 12.0–30.0 months).